THERAPY FOR COMPLICATION OF DIABETES

摘要

PROBLEM TO BE SOLVED: To provide a method for controlling the elevation of blood glucose and/or enhancing insulin sensitivity in a human subject having diabetic nephropathy so that progression of the diabetic nephropathy is arrested, slowed, retarded or stabilized.SOLUTION: At least one kind of selective endothelin A (ET) receptor antagonist selected from the group consisting of ambrisentan, atrasentan, avosentan, BMS-193884, BQ-123, CI-1020, clazosentan, darusentan, edonentan, S-0139, SB-209670, sitaxsentan, TA-0201, tarasentan, TBC-3711, tezosentan, YM-598, ZD-1611, ZD-4054, and salts, esters, prodrugs, metabolites, tautomers, racemates and enantiomers thereof, is administered to a human subject having diabetic nephropathy. The selective ETreceptor antagonist is preferably administered in combination with an antidiabetic, anti-obesity or antidyslipidemic agent.